Proper usage and dosage are crucial for the therapeutic effect of Agamree (vamorolone). This medication is mainly indicated for patients aged 4 years and above with Duchenne Muscular Dystrophy (DMD), and the dosage should be adjusted based on individual conditions. 

Agamree (Vamorolone) Usage and Dosage Instructions

This article will detail the recommended dosage, administration method and precautions of Agamree to help patients use the medication scientifically and standardly, ensure a good therapeutic effect and reduce the risk of adverse reactions.

1. Evaluation Before Initial Medication

Before initiating Agamree treatment, all necessary immunizations should be completed in accordance with immunization guidelines. For live vaccines or attenuated live vaccines, vaccination should be completed at least 4 to 6 weeks before starting Agamree.

2. Administration Information

The recommended usual dose is 6 mg/kg orally once daily, preferably with meals; for patients weighing more than 50 kg, the maximum daily dose is 300 mg. Some patients may respond to a dose of 2 mg/kg per day, and the dose can be reduced to 2 mg/kg per day based on individual tolerance.

3. Recommended Dosage for Patients with Hepatic Impairment

For patients with mild (Child-Pugh A) to moderate (Child-Pugh B) hepatic impairment, the recommended dose is 2 mg/kg orally once daily, preferably with meals; for patients weighing more than 50 kg, the maximum daily dose is 100 mg. The dose can be appropriately reduced according to individual tolerance.

4. Important Preparation and Administration Procedures

Shake the Agamree oral suspension well for approximately 30 seconds before use.

Use only the oral syringe provided with the product: draw the appropriate dose into the syringe and administer the liquid directly into the mouth.

Any remaining liquid in the opened bottle should be discarded if not used within 3 months.

5. Switching from Other Corticosteroids to Agamree

Patients can switch from oral corticosteroids (such as prednisone or prednisolone) to Agamree without interruption, and there is no need to reduce the dose of corticosteroids in advance, which reduces the risk of adrenal insufficiency. For patients who have been receiving oral corticosteroids for a long time, the switch can start at 6 mg/kg per day.

6. Dosage Adjustment When Used Concomitantly with Strong CYP3A4 Inhibitors

When used concomitantly with strong CYP3A4 inhibitors (such as itraconazole), the recommended dose is adjusted to 4 mg/kg orally once daily, preferably with meals; for patients weighing more than 50 kg, the maximum daily dose is 200 mg. The dose can be appropriately reduced according to individual tolerance.

7. Dose Tapering When Discontinuing Medication

If the medication has been used continuously for more than one week, the dose of Agamree must be gradually reduced to lower the risk of adrenal insufficiency caused by sudden discontinuation.